Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 11, 2025

Core Viewpoint - Humacyte, Inc. is set to release its financial results for Q2 2025 on August 11, 2025, and will provide a corporate and financial update during a conference call [1] Group 1: Company Overview - Humacyte, Inc. is a clinical-stage biotechnology platform company focused on developing universally implantable, bioengineered human tissues at commercial scale [2] - The company has received FDA approval for its acellular tissue engineered vessel (ATEV) for vascular trauma in December 2024 and is conducting late-stage clinical trials for other vascular applications [2] - Humacyte's ATEV has received multiple designations, including Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the FDA [2] Group 2: Financial and Conference Call Details - The financial results for the quarter ended June 30, 2025, will be released on August 11, 2025, with a conference call scheduled for 8:00 a.m. ET [1] - Investors can access the conference call via specific dial-in numbers and a conference ID, with a webcast available 15 minutes prior to the call [1]